Lumenis and Trimedyne Settle Litigation YOKNEAM, Israel, Dec. 16 /PRNewswire-FirstCall/ -- Lumenis Ltd. and Trimedyne, Inc. (BULLETIN BOARD: TMED) today announced they have agreed to a settlement of the litigation between them. Under the terms of the settlement, Lumenis and Trimedyne have agreed to enter into a long term commercial arrangement covering the manufacture by Trimedyne and sale by Lumenis of certain side fire and angle fire fibers, used with Lumenis' lasers particularly in orthopedics, urology and spinal surgery. The settlement includes certain other confidential terms. The arrangement will give Lumenis immediate entry into the market for side-firing laser devices for use in spinal treatments, one of the fastest growing segments of the healthcare field. Trimedyne's side-firing Laser Needles, which are only one-twelfth of an inch in diameter, are the leading laser devices used in the outpatient treatment of herniated or ruptured lumbar discs in the spine. The laser procedure is usually performed with local anesthetic in about 20-30 minutes. Patients typically leave the hospital or surgery center within an hour after the procedure, with only a Band-Aid on the puncture. Most can return to light daily activities within a few days. About Lumenis Lumenis develops, manufactures, and markets state-of-the-art proprietary laser and intense pulsed light devices. Its systems are used in a variety of aesthetic, ophthalmic, surgical and dental applications, including skin treatments, hair removal, non-invasive treatment of vascular lesions and pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy, benign prostatic hyperplasia, open angle glaucoma, diabetic retinopathy, secondary cataracts, age-related macular degeneration, vision correction, neurosurgery, dentistry and veterinary. For more information about Lumenis and its products log on to http://www.lumenis.com/ About Trimedyne Trimedyne is a leading manufacturer of surgical lasers and proprietary disposable and reusable fiber optic devices for applications in a variety of minimally invasive surgical procedures in orthopedics (discectomy and arthroscopy), lithotripsy (fragmentation of stones), ENT surgery, gynecology, gastrointestinal surgery and general surgery. For product, financial or other information, visit Trimedyne's website at http://www.trimedyne.com/. The statements in this press release that are not historical facts are forward-looking statements which are subject to risks and uncertainties. Lumenis' actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of Lumenis' products, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, Lumenis' international operations and Lumenis' ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which Lumenis is subject; uncertainties relating to Lumenis' continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q. Contacts: Kevin Morano CFO 212-515-4187 DATASOURCE: Lumenis Ltd. CONTACT: Kevin Morano, CFO of Lumenis Ltd., +1-212-515-4187 Web site: http://www.lumenis.com/ http://www.trimedyne.com/

Copyright